Singapore-based firm to start human trials for Covid-19 treatment
Team Udayavani, Jun 12, 2020, 11:02 AM IST
Tychan, Singaporean biotechnology firm, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.
TY027 is being explored for its ability to slow down the progression of Covid-19 and speed up recovery, and its potential to provide temporary protection against infection
It is said that if phase one is successful, Tychan will seek approval for the antibody to be administered to a larger population of volunteer patients in subsequent trials.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Russia bans Biden’s wife, daughter from entry
Regrettable that still no agreement on Constitutional basis for holding elections in Libya: India
48 migrants die after trailer abandoned in Texas heat
Cyberattack forces Iran steel company to halt production
Sri Lanka to operate only essential services till July 10 amidst acute fuel shortage
MUST WATCH
Latest Additions
Zubair’s ‘objectionable’ tweet of 2018 led to Twitter storm with ‘hate’ speeches: Delhi Police
2 detained for killing tailor in Rajasthan’s Udaipur
Maha CM Thackeray chairs cabinet meeting, first after taking away rebel ministers’ portfolios
Stinking toilets on trains: Railways deploys senior officials for inspection
Taapsee Pannu on teaming up with SRK in ‘Dunki’: It’s a golden opportunity